Overview

Dapagliflozin Efficacy and Action in NASH

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.

Phase:

Phase 3

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Treatments:

Dapagliflozin